Please use this identifier to cite or link to this item:
Title: Liposomal formulation of ChimeraT, a multiple T-cell epitope-containing recombinant protein, is a candidate vaccine for human Visceral Leishmaniasis.
Authors: Lage, Daniela Pagliara
Ribeiro, Patrícia Aparecida Fernandes
Dias, Daniel Silva
Mendonça, Débora Vasconcelos Costa
Ramos, Fernanda Fonseca
Carvalho, Lívia Mendes
Steiner, Bethina Trevisol
Tavares, Grasiele de Sousa Vieira
Martins, Vivian Tamietti
Machado, Amanda Sanchez
Silva, João Augusto Oliveira da
Santos, Thaís Teodoro de Oliveira
Freitas, Camila Simões de
Oliveira, Jamil Silvano de
Roatt, Bruno Mendes
Ávila, Ricardo Andrez Machado de
Humbert, Maria Victoria
Christodoulides, Myron
Coelho, Eduardo Antônio Ferraz
Keywords: Saponin
Th1-type immunity
Issue Date: 2020
Citation: LAGE, D. P. et al. Liposomal formulation of ChimeraT, a multiple T-cell epitope-containing recombinant protein, is a candidate vaccine for human Visceral Leishmaniasis. Vaccines, v. 8, n. 2, artigo 289, jun. 2020. Disponível em: <>. Acesso em: 10 jun. 2021.
Abstract: Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results: Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions: Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.
ISSN: 2076-393X
metadata.dc.rights.license: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( Fonte: o PDF do artigo.
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_LiposomalFormulationChimera.pdf2,64 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.